"If patients have one feature, that is bad, and if they have two or more, that is really bad," he said. "Regardless of ...

Researchers from Helmholtz Munich and the Technical University of Munich have developed a novel method to track cancer ...

Rapid advances have revolutionized the treatment of multiple myeloma, providing better disease control and prolonging survival. Patients are living years longer, thanks to novel combination therapies ...

In patients with a precursor condition for multiple myeloma, the multiple myeloma-like score helps to predict who is at a higher risk of progressing to active cancer.

A growing number of physicians are starting to shift their thinking about multiple myeloma’s prognosis. For years, patients have been told that multiple myeloma is treatable but not curable. Yet data ...

Several studies have been conducted, but questions remain about where such therapies will fit into multiple myeloma treatment strategies.

Peripheral blood absolute lymphocyte count at diagnosis is an effective biomarker that can be used to risk-stratify patients with multiple myeloma, according to retrospective study results ...

Traditionally carrying a dire prognosis, the treatment paradigm for multiple myeloma is changing, with CAR T therapies, bispecifics and more contributing to multifaceted regimens unique to each ...

Daratumumab, an anti-CD38 monoclonal antibody, has been approved for the treatment of multiple myeloma. Data are needed regarding the use of daratumumab for high-risk smoldering multiple myeloma, a ...

Are an adult with relapsed or refractory multiple myeloma Have tried at least four previous lines of treatments for multiple myeloma, including: Immune system modulators (help boost the immune ...

Speakers on precursor disease addressed distinctions between MGUS and smoldering multiple myeloma, risk stratification, and new thinking on the role of immunological aging, especially how it ...